FOLH1 expression

Targeting LGALS9 enhances DC-mediated CD8+ T-cell immunity and synergistically augments the therapeutic efficacy of tumor vaccines, representing a promising immunotherapeutic strategy for prostate cancer.

Tumor biopsies confirmed radioactivity. 89Zr-CB307 selectively accumulated in PSMA-positive tumor lesions without specific uptake in PSMA-positive-normal or lymphoid tissues in patients with mCRPC.

Elderly mCRPC patients undergoing 177Lu-PSMA-617 radioligand therapy achieve meaningful PSA50 response rates, with baseline hemoglobin, prior docetaxel exposure, tumor burden, PSMA expression level, and ALP being independent predictors of response. Treatment response is closely associated with improved quality of life and mental health outcomes, with response rates improving with additional therapy cycles. These findings provide evidence-based guidance for precision patient selection, treatment monitoring, and individualized optimization strategies for 177Lu-PSMA-617 therapy.

This pilot study demonstrated an increase in SUVmax in PSMA-positive prostate cancer lesions following a short-term seven-day course of dutasteride. Short-term dutasteride treatment prior to PSMA-PET imaging may have the potential to enhance detection rates in patients with prostate cancer. Further studies are needed to investigate this effect in larger patient populations.

PSMA PET-derived volumetric parameters, particularly PSMA tumor volume, provide robust prognostic information in mCRPC patients treated with abiraterone or enzalutamide. When combined with early PSA kinetics, these imaging biomarkers enable improved risk stratification and may support more individualized treatment strategies. Prospective multicenter studies are warranted to validate these findings.

P1, N=18, Active, not recruiting, Shanghai Changzheng Hospital | Trial completion date: Dec 2025 --> Dec 2026 | Trial primary completion date: May 2025 --> May 2026 | Recruiting --> Active, not recruiting

P1, N=3, Active, not recruiting, Shanghai Changzheng Hospital | Recruiting --> Active, not recruiting | Trial completion date: Nov 2025 --> Nov 2026 | Trial primary completion date: Nov 2025 --> Jul 2026

Question The normal range for [18F]PSMA-1007 uptake values in PROMISE reference tissues are not well documented, challenging standardized lesion categorization in prostate cancer PET interpretation. Findings In a multicenter cohort, splenic [18F]PSMA-1007 uptake exceeded parotid gland uptake in a notable subgroup (15%), leading to situations where PSMA expression scoring according to the PROMISE framework cannot be applied as intended. Clinical relevance Unexpectedly high splenic uptake relative to parotid gland uptake of [18F]PSMA-1007 in some patients may affect lesion categorization; careful interpretation is advised.

Over a period of 10 y, our center treated 766 patients with prostate cancer using 177Lu-PSMA (177Lu-PSMA-617 or 177Lu-PSMA I&T)...Two patients received complement inhibition with eculizumab, which improved hematologic features without meaningful renal recovery. 177Lu-PSMA-associated TMA is a rare but a potentially severe complication of treatment. The contribution of initial versus cumulative renal absorbed dose remains unclear, and early dosimetry may help identify at-risk patients.

The MNT-antiPSMA construct demonstrated the capacity to accumulate specifically in the nuclei of prostate cancer cells with both low and high PSMA expression. Conversely, MNT-GRP exhibited selective nuclear entry exclusively in cells characterized by high GRPR expression.

Subsequent studies focused on the in vitro stability and cellular interaction with two prostate cancer cell lines with different PSMA expression levels, in both 2D and 3D cell cultures, to assess effective targeting. Results indicate that radiolabeled AuNPs exhibit selective interaction with PSMA-expressing cells and present a stronger in vitro cytotoxic effect when functionalized with the PSMA molecule, confirming their potential as theranostic agents and warranting further investigation in LNCaP tumor-bearing mice.

FOLH1 may be involved in tumor progression by regulating amino acid metabolic pathways and the immune microenvironment. It is a promising pan-cancer prognostic marker and synergistic target for immunotherapy.